What the company or idea is
Boehringer Ingelheim is a privately owned pharmaceutical company founded in 1885 in Ingelheim am Rhein, Germany. It works in human pharmaceuticals, animal health, and biopharmaceuticals. It is fully owned by three families and operates globally with over 54,000 employees in 76 countries.
How it actually makes money
Boehringer Ingelheim makes money from selling human pharmaceuticals, animal health products, and biopharmaceuticals. It operates 20 production plants in 13 countries and runs R&D facilities across five sites.
What works
The model of private ownership enables consistent capital allocation to R&D and manufacturing—evidenced by formal research department launch in 1917 and five global R&D sites. Its early move into bacterial fermentation gave it a durable technical edge in biopharma before the term existed.
What does not
The sources do not establish revenue, profit, valuation, market share, drug approval rates, clinical trial success, pricing strategy, or cost of goods sold. They say nothing about current pipeline performance, regulatory setbacks, or commercial failures.
What to take from it
Its longevity rests on two deliberate, interlocking choices: vertical integration into bioproduction (starting with lactic acid in the 1890s) and binding employee loyalty through welfare infrastructure (health insurance in 1902, pension in 1912, canteen in 1917). Neither was incidental.
Is it worth your time
Yes—if you are studying how private ownership shapes long-term R&D investment, employee welfare policy, or the industrialisation of biotechnology. No—if you assume scale requires public markets or that early biotech was accidental.